Company Description
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States.
The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension.
The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA.
Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
| Country | United States |
| Founded | 2006 |
| IPO Date | Jul 25, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 274 |
| CEO | Pravin Dugel |
Contact Details
Address: 15 Crosby Drive Bedford, Massachusetts 01730 United States | |
| Phone | 781 357 4000 |
| Website | ocutx.com |
Stock Details
| Ticker Symbol | OCUL |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001393434 |
| CUSIP Number | 67576A100 |
| ISIN Number | US67576A1007 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Pravin U. Dugel M.D. | Executive Chairman, President and Chief Executive Officer |
| Dr. Jeffrey S. Heier M.D. | Chief Scientific Officer |
| Dr. Peter K. Kaiser M.D. | Chief Development Officer |
| Donald Notman Jr. | Chief Financial Officer, Chief Operating Officer and Principal Accounting Officer |
| Dr. Peter K. Jarrett Ph.D. | Chief Technical Officer |
| William S. Slattery Jr. | Vice President of Investor Relations |
| Todd D.C. Anderman J.D. | Chief Legal Officer and Corporate Secretary |
| William H. Ransone II | Vice President of Global Sales and Marketing |
| Barry Rubenstein M.S. | Chief Human Resources Officer |
| Steve Meyers | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 17, 2025 | SCHEDULE 13G/A | Filing |
| Oct 8, 2025 | 144 | Filing |
| Oct 2, 2025 | 144 | Filing |
| Oct 2, 2025 | 144 | Filing |
| Sep 30, 2025 | 424B5 | Filing |
| Sep 30, 2025 | 8-K | Current Report |
| Sep 30, 2025 | 8-K | Current Report |
| Sep 30, 2025 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Sep 2, 2025 | 144 | Filing |
| Aug 25, 2025 | 144 | Filing |